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1. Introduction
Fabry disease is a rare lysosomal disorder that has a prevalence of 1 in 40,000 males.[1] This
disease follows x-linked inheritance and the individuals affected with the disease show multi
system disorders that are present at birth and signs and symptoms worsen with time. The GLA
gene mutation leads to the deficiency of an enzyme alpha galactidose A which leads to the
progressive accumulation of globotriacylceramide (GB3) deposits in a variety of cells including
those in kidneys, and the autonomic the cardiovascular systems.[2-4]
The ocular manifestations of Fabry disease includes a cornea verticillata which is a “vortex
whorl” like corneal opacity. It is the most common finding and is seen in all hemizygotes and
majority (up to 70%) of hetrozygotes.[5] The cornea verticillata is the outcome of the deposit
of GB3 in the basal layer of the corneal epithelium. The cornea verticillata is visible using a
slitlamp biomicroscope and in-vivo confocal microscopic studies have shown that even when
the cornea verticillata may not be visible using a slitlamp there are intracellular inclusion
bodies in the basal epithelial cells.[6] To a lesser degree and fewer Fabry disease patients have
subtle lenticular deposits which is the Fabry cataract.[7] The Fabry cataract tends to be off axis
dendritic or subcapsular opacities along the posterior suture lines. It is believed that patients
with cornea verticillata will not have any visual symptoms due to the deposits. [7-9]
The role of the cornea and the crystalline lens is to provide the eye with necessary refractive
power and unhindered path to the light rays that pass through them. To this accord the corneal
physiology is finely tuned and causes the least amount of scatter of light rays in ocular healthy
individuals. It can be hypothesized that individuals with Fabry disease could have problems
with visual function given that both the cornea and the crystalline lens have deposits of GB3
and opacities. It can further be hypothesized that the vision problems would be present and
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will be worst at night time when compared to the day time, with patients with Fabry disease
having additional problems of glare, blurry vision or dim vision (contrast sensitivity issues).
The patients with Fabry disease also experience anhydrosis or hypohydrosis as one of the
symptom. This is due to the neurological manifestations of the disease. Prior reports have
suggested that patients with Fabry disease may have deposits of GB3 in the ganglia or the
lacrimal gland itself.[10-12] It can be hypothesized that patients with Fabry disease could also
have symptoms of dry eyes.
The present study utilized an ocular symptom survey instrument to evaluate for the symptoms
of general ocular problems like itching, tearing, dryness, burning sensation, sensation of
foreign body or difficulty in vision or asthenopic symptoms in patients with Fabry disease and
compared the findings to healthy controls.
2. Materials and methods
2.1. Study participants
A total of 95 individuals (75 patients with Fabry disease and 20 healthy controls) completed
the survey. The mean age and standard deviation (SD) of the patients in the Fabry group and
the control group was 32.5 and SD 19.1 years and 42.6 SD 14.7 years respectively. Ninety six
percent of the participants completed all the survey questions, with 4 individuals not answer‐
ing the question about “soreness and fatigue” of eyes.
The survey was administered live at the conferences for lysosomal disease storage which was
conducted by the Fabry Support and Information Group in San Diego California, USA and the
National Fabry Disease Foundation in Greensboro, North Carolina, USA. These events were
attended by individuals that had a confirmed case of Fabry disease or by a family member
who were tested and confirmed of being healthy and did not have Fabry disease or healthy
spouse. The participants were instructed to answer the survey questions with regards to their
self-perceived ocular and vision status when they were wearing optimal refractive correction.
Data was collated and analyzed in a masked fashion with the data entry performed by a
separate individual and the statistical analysis performed by the author.
2.2. Survey instrument
A modified survey instrument that was utilized by Lee et al [13] to investigate the ocular and
visual symptoms in glaucoma patients was utilized in the present study. The survey instru‐
ment proposed by Lee et al[13] was called the Glaucoma Symptom Scale (GSS) and is a simple
10 question survey that was developed by modifying the survey used in the Ocular Hyper‐
tension Treatment Study. The GSS was tested and validated on a group of glaucoma patients
in four tertiary care glaucoma centers. This survey instrument was administered to both
patients with Fabry disease and their healthy family members (controls).
The survey administered in the present study is shown in Figure 1. The major difference
between the GSS and the survey administered in the present study is the scale of the symptoms.
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The GSS graded the symptoms in 4 point scale whereas the present study utilized a 6 point
scale. The larger scale in the present survey allowed evaluating a wide range of symptom level
as it was likely that the ocular symptoms in patients with the ocular manifestations of Fabry
disease could be mild or minimal. The GSS survey instrument mainly evaluated for dryness
and tear film and ocular surface issues in questions 1 to 4 and 7, whereas question 4 is designed
to evaluate for general fatigue or asthenopic symptoms. The survey instruments question
number 6, 8-10 were designed to evaluate vision related problems primarily the difficulty in
contrast sensitivity issues, day time night time vision and glare respectively.
Figure 1. Survey instrument administered to the study participants; Survey instrument used in the study was devel‐
oped by Lee et al [13]. The only modification made to the survey was the scale. The present study used a 6 point scale
where as the survey instrument used by Lee et al had a 4 point scale.
2.3. Statistical analysis
The difference in the mean age between the groups was analyzed using a one–way analysis
of variance (ANOVA). The severity for each variable was graded in an ordinal scale with 1
being “almost never” and 6 as “almost always”. A Mann-Whitney test was performed to
evaluate the median difference between the Fabry group and the healthy control for each
symptom survey question. A p-value of <0.05 was considered to be significant.
3. Results
The mean age of the control group was greater than the mean age of the Fabry group (ANOVA
F=4.75; p=0.03). The table-1 provides the mean symptom severity score for the Fabry group
and the control group and the p-value obtained using the Mann-Whitney test.
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Symptom Mean Severity Score p-valueFabry group Control group
1 Burning /stinging 1.9 1.5 0.06
2 Tearing 2.0 1.9 0.2
3 Dryness 2.3 1.5 0.02
4 Itching 2.0 1.8 0.3
5 Soreness/tiredness 2.4 1.7 0.009
6 Blurry/Dim vision 2.2 1.6 0.02
7 Feeling of something in your eyes 2.0 1.5 0.07
8 Hard to see in daylight; I need to wear sunglasses 2.4 1.7 0.15
9 Hard to see in dark places 2.6 1.6 0.01
10 Halos around light 2.4 1.7 0.01
p-value in bold are significant at p<0.05 and in bold and italics are significant p <0.01
Table 1. Symptoms surveys and the median severity of groups and statistical significance
Of the survey instruments items, it was found that patients in the Fabry group had more
complaints of “dryness” of eyes (p=0.02). The Fabry group also showed significantly greater
symptom  severity  score  and  complained  of  “Blurry/Dim  vision”,  “hard  to  see  in  dark
places” and “halos around light” (p=0,02, 0.01 and 0.01 respectively). The Fabry group also
had a  mean severity  score  for  “soreness/tiredness”  significantly  higher  than the  control
group (p=0.009).  The tally of number of participants with symptoms and without symp‐
toms is given in Table 2
4. Discussion
The survey instrument (GSS) utilized in this study was designed by Lee et al [13] to study the
ocular and vision issues in glaucoma patients with the purpose of surveying daytime and night
time vision, contrast sensitivity, glare, dryness and tear film related problems. The present
study utilized the GSS survey instrument to identify ocular and visual symptoms in the Fabry
disease and ocular healthy controls. The study results indicate that compared to healthy
controls, the patients with Fabry disease had greater ocular symptom severity score in
particularly areas related to night vision, contrast sensitivity and glare. Further they also have
greater symptom severity score and complaint of soreness/tiredness and dry eyes.
Prior reports have indicated that patients with Fabry disease do not have any visual problems
due to the cornea verticillata. [7-9] This is perhaps true to the point that the cornea verticillata
may not cause a decline in Snellen visual acuity charts that uses 100% contrast optotypes (black
letters on white background) as long as the patients wear appropriate refractive error correc‐
tion. The findings of this study indicate that the symptoms of “dim vision”, “hard to see in
dark places” perhaps indicates decrease in contrast sensitivity or difficulty in identifying
targets in day to day life that are in shades of grey not of 100% contrast.. The Fabry group also
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had a symptom severity score significantly higher for the survey item seeing “Halo around
lights” which is perhaps a result due to the scatter or glare problems that patients experience.
This problem may perhaps be further exaggerated at night time.
Symptoms Problem No Problem
Burning and stinging Disease 38 37
No disease 5 15
Tearing Disease 44 31
No disease 11 9
Dryness* Disease 44 31
No disease 7 13
Itching Disease 44 31
No disease 9 11
Soreness tiredness* Disease 52 23
No disease 6 14
Blurry, Dim vision* Disease 48 27
No disease 7 13
Feeling something in your eyes Disease 40 35
No disease 6 14
Hard to see in daylight, I need sunglasses Disease 39 36
No disease 7 13
Hard to see in dark places* Disease 45 30
No disease 7 13
Halos around light* Disease 44 31
No disease 6 14
* indicates symptoms that was statistically significant greater severity score between the groups
Table 2. The tally of study participants that reported experiencing symptoms in the Fabry group and the control group
The vision problems related to scotopic (night) vision, contrast sensitivity and glare are most
likely due to the deposits of GB3 in corneal epithelium and lens which causes increased scatter
of light rays and decreased transmittance of light (See figures 2 A-C). The confocal microscopic
studies have revealed that even when there is no clinically visible cornea verticillata the basal
layer of the epithelium show hyper reflectivity due to the intracellular inclusion bodies. Thus
although one can expect the symptom severity score to be related to the amount of corneal
deposits visible, the patients that do not have visible deposits or cornea verticillata may still
have some visual problems given that have the intracellular inclusion bodies in the corneal
epithelial cells.
The Fabry group also had greater complaints of “dryness” compared to the control group. This
could be due to the fact that GB3 gets deposited both in the ganglia and the lacrimal gland.
[10-12] Prior researchers have also suggested that patients with Fabry disease can have a dry
Fabry Disease – Ocular Manifestations and Visual Symptoms
http://dx.doi.org/10.5772/58677
389
eye syndrome.[9] The report of this survey quantifies that patients may have a subtle yet
clinically significant dry eye.
The patients with Fabry disease also complain of lack of energy or chronic fatigue. [14] It is
intriguing to note that symptom survey score for “soreness/tiredness of eyes was significantly
greater than the control group. This could have multiple reasons. The simplest explanation is
they experience chronic fatigue of their body and thus also experience “soreness/tiredness”
Figure 2. Cornea verticillata in patients with Fabry disease A: Top panel: Cornea verticillata giving a even spread of
smear of deposits throughout the cornea. B: Middle panel: A vortex like deposits. C: Bottom panel: A subtle verticillata
in a patient with Fabry disease
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with eyes. Although it is possible that dry eye, dim vision may contribute to some of these
asthenopic problems. It will be interesting to see if this symptom severity score would decrease
if appropriate therapy using glare filters, contrast enhancing filters or treatment for dry eyes
was administered.
The cornea verticillata in patients with Fabry disease can vary significantly; they can be absent,
subtle, or dramatic in appearance. The figures 2 A-C provide slit lamp photographs of cornea
verticillata in patients with known Fabry disease. The figures 3 A B provide images of of
conjunctival vascular findings in patients with Fabry disease. It should be noted that the cornea
verticillata is not limited to Fabry disease and patients on medication like amiodorone or
aminoquinolones on chronic use can have similar corneal appearance.[7] It can be postulated
that any person with cornea verticillata can have vision problems pertaining to night time,
contrast discrimination and glare.
Figure 3. Conjunctival tortousity with aneurysms like out pouching (A: Top and B: Bottom panel)
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This is first report to my knowledge that has evaluated the ocular symptom severity survey
in patients with Fabry disease. Future studies are needed and should look at quantifying the
problems and symptoms with contrast sensitivity function testing, glare testing and investi‐
gate tear function tests to evaluate the vision related difficulty and dry eye problems.
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